CD4 count, viral load and parasite density of HIV positive individuals undergoing malaria treatment with dihydroartemisinin in Benin City, Edo state, Nigeria.
OBJECTIVE
A prospective study on 72 HIV infected and 33 HIV negative individuals undergoing malaria treatment with dihydroartemisinin (Cotecxin) was undertaken to compare CD4 cells count, viral load and parasite density at two time-points, a baseline visit and a 9-day post-treatment visit.


METHODS
CD4 count and viral load of the subjects were estimated using Dynabeads T4-T8 Quantification Protocol (Dyneal Biotech, Norway) and Amplicor HIV-1 Monitor Test respectively (Roche, United Kingdom).


RESULTS
There was a significant decrease in CD4 count at 9-day post-treatment when compared with baseline value (p < 0.05) in HIV infected individuals with CD4 < or =200 cells/microl. Also, the 9-day post-treatment viral load value was statistically higher than the baseline value (p < 0.05). In HIV positive patients with CD4 >200 cells/microl, a marked significant increase was obtained when the mean viral load at baseline was compared to the 9-day post-treatment visit value (p <0.05). The mean parasite density in HIV positive subjects was statistically higher when compared to that of HIV negative individuals at baseline and 9-day post-treatment (p < 0.05).


CONCLUSIONS
The study as such may not confirm the impact of malaria infection on progression to AIDS, incorporating effective malaria control in HIV management programmes may improve tremendously the quality of life of HIV infected individuals.
Tatfeng
Y M
YM
Lahor Public Health and Research Centre, Benin City, Nigeria/Igbinedion University, Okada. youtchou@yahoo.com
Ihongbe
J C
JC
Okodua
M
M
Oviasogie
E
E
Isibor
J
J
Tchougang
S
S
Tambo
E
E
Otegbeye
T
T
D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002648:Child; D002675:Child, Preschool; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications*; D015497:HIV-1; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008288:Malaria / Q000150:complications / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D009549:Nigeria; D011446:Prospective Studies; D012717:Sesquiterpenes / Q000627:therapeutic use*; D014504:Urban Health; D019562:Viral Load
D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; C039060:artenimol